Venturi Wealth Management LLC Boosts Position in Moderna, Inc. (NASDAQ:MRNA)

Venturi Wealth Management LLC raised its holdings in Moderna, Inc. (NASDAQ:MRNA) by 286.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 896 shares of the company’s stock after purchasing an additional 664 shares during the quarter. Venturi Wealth Management LLC’s holdings in Moderna were worth $37,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB lifted its stake in Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after buying an additional 587 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after buying an additional 389 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of Moderna by 53.1% during the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock worth $47,000 after buying an additional 388 shares during the last quarter. EMC Capital Management increased its holdings in shares of Moderna by 311.2% during the 4th quarter. EMC Capital Management now owns 1,250 shares of the company’s stock worth $52,000 after buying an additional 946 shares during the last quarter. Finally, Larson Financial Group LLC boosted its position in shares of Moderna by 53.5% during the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after purchasing an additional 317 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the sale, the insider now owns 19,717 shares of the company’s stock, valued at $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last 90 days, insiders have sold 2,664 shares of company stock valued at $115,210. Corporate insiders own 15.20% of the company’s stock.

Wall Street Analyst Weigh In

MRNA has been the subject of several recent research reports. HSBC raised shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target for the company in a research report on Monday, November 18th. Wolfe Research started coverage on shares of Moderna in a research note on Friday, November 15th. They set an “underperform” rating and a $40.00 price target on the stock. Bank of America cut their price target on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research note on Tuesday, February 11th. Piper Sandler reiterated an “overweight” rating and set a $69.00 price target (down from $115.00) on shares of Moderna in a research note on Monday, November 18th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $40.00 price target on shares of Moderna in a research note on Tuesday, February 18th. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Moderna has an average rating of “Hold” and a consensus price target of $60.63.

Moderna Stock Down 2.0 %

Shares of Moderna stock opened at $33.22 on Wednesday. The firm has a market cap of $12.78 billion, a price-to-earnings ratio of -3.58 and a beta of 1.59. Moderna, Inc. has a 52-week low of $29.25 and a 52-week high of $170.47. The company’s 50-day simple moving average is $37.89 and its 200-day simple moving average is $52.10.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.